Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Large Growth in Short Interest

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,280,000 shares, an increase of 19.6% from the February 28th total of 1,070,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is presently 0.7 days. Currently, 1.2% of the shares of the company are sold short.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Juncture Wealth Strategies LLC raised its holdings in shares of Cellebrite DI by 0.8% in the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock worth $1,322,000 after purchasing an additional 505 shares during the period. Bosun Asset Management LLC lifted its position in Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company’s stock worth $954,000 after acquiring an additional 584 shares in the last quarter. TD Waterhouse Canada Inc. grew its holdings in Cellebrite DI by 1.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company’s stock valued at $1,046,000 after purchasing an additional 859 shares in the last quarter. Strategic Advisors LLC boosted its stake in shares of Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock valued at $641,000 after buying an additional 950 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock worth $299,000 after purchasing an additional 1,463 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $18.77 on Friday. The company has a market cap of $4.49 billion, a P/E ratio of -13.50, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The business has a fifty day moving average of $20.53 and a two-hundred day moving average of $19.94. Cellebrite DI has a one year low of $10.25 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Sell-side analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on CLBT. Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI has a consensus rating of “Buy” and a consensus target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.